$DARE
Dare Bioscience, Inc.

2016 Q4 Form 10-Q Financial Statement

#000156459016027350 Filed on November 03, 2016

View on sec.gov

Income Statement

Concept 2016 Q4 2015 Q4
Revenue $766.0K $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $190.0K $2.870M
YoY Change -93.38% 9.96%
% of Gross Profit
Research & Development $3.184M $7.157M
YoY Change -55.51% 52.24%
% of Gross Profit
Depreciation & Amortization $60.00K
YoY Change 50.0%
% of Gross Profit
Operating Expenses $5.274M $10.03M
YoY Change -47.41% 37.23%
Operating Profit
YoY Change
Interest Expense $457.0K $689.0K
YoY Change -33.67% 322.7%
% of Operating Profit
Other Income/Expense, Net -$437.0K -$687.0K
YoY Change -36.39% 332.08%
Pretax Income -$200.0K -$10.71M
YoY Change -98.13% 43.37%
Income Tax
% Of Pretax Income
Net Earnings -$4.945M -$10.72M
YoY Change -53.85% 43.51%
Net Earnings / Revenue -645.56%
Basic Earnings Per Share
Diluted Earnings Per Share -$227.3K -$3.909M
COMMON SHARES
Basic Shares Outstanding 27.44M
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q4 2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $40.00K $75.91M
YoY Change -99.95% 48.35%
Cash & Equivalents $44.61K $219.4K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables $823.0K $1.390M
Other Receivables $0.00
Total Short-Term Assets $36.79M $77.30M
YoY Change -52.41% 46.31%
LONG-TERM ASSETS
Property, Plant & Equipment $668.0K $576.0K
YoY Change 15.97% 68.42%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $12.68K $347.0K
YoY Change -96.35% 61.4%
Total Long-Term Assets $898.0K $923.0K
YoY Change -2.71% 65.71%
TOTAL ASSETS
Total Short-Term Assets $36.79M $77.30M
Total Long-Term Assets $898.0K $923.0K
Total Assets $37.69M $78.23M
YoY Change -51.82% 46.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.446M $2.226M
YoY Change -35.04% 77.37%
Accrued Expenses $4.611M $6.459M
YoY Change -28.61% 77.06%
Deferred Revenue
YoY Change
Short-Term Debt $700.0K $0.00
YoY Change
Long-Term Debt Due $7.650M
YoY Change 145.19%
Total Short-Term Liabilities $755.2K $16.34M
YoY Change -95.38% 102.67%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $12.67M
YoY Change -100.0%
Other Long-Term Liabilities $1.206M $473.0K
YoY Change 154.97% 6657.14%
Total Long-Term Liabilities $7.638M $13.15M
YoY Change -41.89% 187685.71%
TOTAL LIABILITIES
Total Short-Term Liabilities $755.2K $16.34M
Total Long-Term Liabilities $7.638M $13.15M
Total Liabilities $755.2K $29.48M
YoY Change -97.44% 265.42%
SHAREHOLDERS EQUITY
Retained Earnings -$727.8K -$161.4M
YoY Change -99.55% 32.51%
Common Stock $17.21K $210.1M
YoY Change -99.99% 25.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$710.6K -$46.95K
YoY Change
Total Liabilities & Shareholders Equity $44.61K $78.23M
YoY Change -99.94% 46.51%

Cashflow Statement

Concept 2016 Q4 2015 Q4
OPERATING ACTIVITIES
Net Income -$4.945M -$10.72M
YoY Change -53.85% 43.51%
Depreciation, Depletion And Amortization $60.00K
YoY Change 50.0%
Cash From Operating Activities -$160.0K -$8.210M
YoY Change -98.05% 46.35%
INVESTING ACTIVITIES
Capital Expenditures -$140.0K
YoY Change 27.27%
Acquisitions
YoY Change
Other Investing Activities $0.00 $20.00K
YoY Change -100.0%
Cash From Investing Activities $0.00 -$110.0K
YoY Change -100.0% 0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 200.0K 6.600M
YoY Change -96.97% -833.33%
NET CHANGE
Cash From Operating Activities -160.0K -8.210M
Cash From Investing Activities 0.000 -110.0K
Cash From Financing Activities 200.0K 6.600M
Net Change In Cash 40.00K -1.720M
YoY Change -102.33% -74.02%
FREE CASH FLOW
Cash From Operating Activities -$160.0K -$8.210M
Capital Expenditures -$140.0K
Free Cash Flow -$8.070M
YoY Change 46.73%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
347000
CY2015Q4 us-gaap Assets
Assets
78225000
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2016-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Trading Symbol
TradingSymbol
CERU
dei Entity Registrant Name
EntityRegistrantName
CERULEAN PHARMA INC.
dei Entity Central Index Key
EntityCentralIndexKey
0001401914
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27435680
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75908000
CY2015Q4 ceru Accounts Receivable Prepaid Expense And Other Current Assets
AccountsReceivablePrepaidExpenseAndOtherCurrentAssets
1394000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
77302000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
576000
CY2015Q4 us-gaap Loans Payable Current
LoansPayableCurrent
7652000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2226000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6459000
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.017
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.012
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.012
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2005-11-28
CY2016Q3 us-gaap Interest Payable Current
InterestPayableCurrent
92000
CY2015Q4 us-gaap Interest Payable Current
InterestPayableCurrent
136000
CY2016Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
301000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
130000
CY2016Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
572000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
753000
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1620000
CY2016Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
135000
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1578000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.015
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.013
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.019
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.020
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.68
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.61
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.61
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.61
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.68
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.63
CY2016Q3 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.48
ceru Restructuring Costs Expected Payment Date
RestructuringCostsExpectedPaymentDate
2017-03-31

Files In Submission

Name View Source Status
0001564590-16-027350-index-headers.html Edgar Link pending
0001564590-16-027350-index.html Edgar Link pending
0001564590-16-027350.txt Edgar Link pending
0001564590-16-027350-xbrl.zip Edgar Link pending
ceru-10q_20160930.htm Edgar Link pending
ceru-20160930.xml Edgar Link completed
ceru-20160930.xsd Edgar Link pending
ceru-20160930_cal.xml Edgar Link unprocessable
ceru-20160930_def.xml Edgar Link unprocessable
ceru-20160930_lab.xml Edgar Link unprocessable
ceru-20160930_pre.xml Edgar Link unprocessable
ceru-ex101_356.htm Edgar Link pending
ceru-ex102_394.htm Edgar Link pending
ceru-ex103_507.htm Edgar Link pending
ceru-ex311_8.htm Edgar Link pending
ceru-ex312_7.htm Edgar Link pending
ceru-ex321_6.htm Edgar Link pending
ceru-ex322_171.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g201611031744438989475.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending